- A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 MutationLu, S.; Yu, Y.; Guo, Q.; Li, Y.; Zhong, D.; Gu, L.; Fang, J.; Han, S.; Pan, P.; Deng, P.; Liu, B.; Wang, M.; Wu, H.; Gao, F.; Lin, W.; Li, J.; Lv, D.; He, S.; Liu, Z.; Pan, C.; Li, J.; Tian, Y.; Yang, N.; Zhang, Y.; Liu, C.; Zhu, X.; Song, Q.; Yu, J.; Fan, S.; Ren, Y.; Shi, M.; Su, W.被引 1
- Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION studyPaik, Paul K.; Garassino, Marina Chiara; Le, Xiuning; Thomas, Michael; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F.; Mazieres, Julien; Cortot, Alexis B.; Raskin, Jo; Viteri, Santiago; Yang, James Chih-Hsin; Ahn, Myung-Ju; Wu, Yi-Long; Zhao, Jun; Adrian, Svenja; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Felip, EnriquetaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
- A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpressionYu, Y.; Dong, W.; Shi, Y.; Wu, R.; Yu, Q.; Ye, F.; Zhou, C.; Dong, X.; Li, X.; Li, Y.; Li, Z.; Pan, Y.; Shen, H.; Wu, D.; Xu, Z.; Wu, J.; Xu, N.; Qin, Y.; Li, J.; Lu, S.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
6被引11阅读
